End-of-day quote
Shanghai S.E.
06:00:00 2024-07-01 pm EDT
|
5-day change
|
1st Jan Change
|
7.17
CNY
|
+0.99%
|
|
+2.58%
|
-23.40%
|
Fiscal Period: December |
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
12,936
|
11,133
|
8,444
|
-
|
-
|
Enterprise Value (EV)
1 |
12,936
|
15,209
|
8,444
|
8,444
|
8,444
|
P/E ratio
|
26.2
x
|
-117
x
|
18.4
x
|
11.9
x
|
16.7
x
|
Yield
|
-
|
-
|
0.28%
|
0.28%
|
0.84%
|
Capitalization / Revenue
|
-
|
1.07
x
|
0.83
x
|
0.66
x
|
0.77
x
|
EV / Revenue
|
-
|
1.07
x
|
0.83
x
|
0.66
x
|
0.77
x
|
EV / EBITDA
|
-
|
9.86
x
|
4.51
x
|
4.59
x
|
4.83
x
|
EV / FCF
|
-
|
-
|
-
|
-
|
-
|
FCF Yield
|
-
|
-
|
-
|
-
|
-
|
Price to Book
|
-
|
1.46
x
|
0.99
x
|
0.89
x
|
0.9
x
|
Nbr of stocks (in thousands)
|
1,173,876
|
1,189,385
|
1,177,697
|
-
|
-
|
Reference price
2 |
11.02
|
9.360
|
7.170
|
7.170
|
7.170
|
Announcement Date
|
3/30/23
|
4/29/24
|
-
|
-
|
-
|
Fiscal Period: December |
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
-
|
10,373
|
10,214
|
12,719
|
10,945
|
EBITDA
1 |
-
|
1,129
|
1,872
|
1,841
|
1,748
|
EBIT
1 |
-
|
430.3
|
896.9
|
1,088
|
914.1
|
Operating Margin
|
-
|
4.15%
|
8.78%
|
8.55%
|
8.35%
|
Earnings before Tax (EBT)
1 |
-
|
-82.87
|
397.5
|
859
|
440.3
|
Net income
1 |
489
|
-93.17
|
463.1
|
725.2
|
513
|
Net margin
|
-
|
-0.9%
|
4.53%
|
5.7%
|
4.69%
|
EPS
2 |
0.4200
|
-0.0800
|
0.3900
|
0.6050
|
0.4300
|
Free Cash Flow
|
-
|
-
|
-
|
-
|
-
|
FCF margin
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
2 |
-
|
-
|
0.0200
|
0.0200
|
0.0600
|
Announcement Date
|
3/30/23
|
4/29/24
|
-
|
-
|
-
|
Fiscal Period: December |
2023 Q1
|
2023 Q2
|
2023 Q3
|
2023 Q4
|
2024 Q1
|
2024 Q2
|
2024 Q3
|
2024 Q4
|
2025 Q1
|
2025 Q2
|
---|
Net sales
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EBITDA
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EBIT
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Operating Margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Earnings before Tax (EBT)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Net income
|
232.3
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Net margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EPS
1 |
0.1900
|
0.1800
|
0.0600
|
-0.4700
|
0.2100
|
0.1600
|
0.0900
|
-0.0600
|
0.1000
|
0.0100
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
4/19/23
|
8/4/23
|
10/27/23
|
4/29/24
|
4/30/24
|
-
|
-
|
-
|
-
|
-
|
Fiscal Period: December |
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
|
-
|
4,076
|
-
|
-
|
-
|
Net Cash position
|
-
|
-
|
-
|
-
|
-
|
Leverage (Debt/EBITDA)
|
-
|
3.612
x
|
-
|
-
|
-
|
Free Cash Flow
|
-
|
-
|
-
|
-
|
-
|
ROE (net income / shareholders' equity)
|
-
|
-1.15%
|
5.57%
|
7.52%
|
5.58%
|
ROA (Net income/ Total Assets)
|
-
|
-0.51%
|
4.4%
|
4.9%
|
-
|
Assets
1 |
-
|
18,194
|
10,526
|
14,801
|
-
|
Book Value Per Share
2 |
-
|
6.430
|
7.220
|
8.020
|
7.950
|
Cash Flow per Share
2 |
-
|
1.240
|
0.8500
|
1.740
|
-
|
Capex
|
-
|
-
|
-
|
-
|
-
|
Capex / Sales
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
3/30/23
|
4/29/24
|
-
|
-
|
-
|
Last Close Price
7.17
CNY Average target price
7
CNY Spread / Average Target -2.37% Consensus |
1st Jan change
|
Capi.
|
---|
| -23.40% | 1.16B | | +55.55% | 816B | | +41.04% | 634B | | -6.83% | 351B | | +17.15% | 323B | | +7.09% | 293B | | +13.60% | 238B | | +1.47% | 222B | | +13.60% | 218B | | +7.87% | 167B |
Other Pharmaceuticals
|